Opko Health Shares Up 2.2% on Insider Buying Activity (OPK)
Opko Health (NYSE:OPK) shares shot up 2.2% during mid-day trading on Thursday after an insider bought additional shares in the company, AnalystRatings.NET reports. The company traded as high as $8.99 and last traded at $8.89, with a volume of 1,511,969 shares changing hands. The stock had previously closed at $8.70.
Specifically, CEO Phillip Md Et Al Frost acquired 30,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, July 8th. The shares were purchased at an average price of $8.58 per share, with a total value of $257,400.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link.
Several analysts have recently commented on the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of Opko Health in a research note on Wednesday, June 25th. They now have a $11.00 price target on the stock, down previously from $11.50. Separately, analysts at TheStreet upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Friday, May 30th. Finally, analysts at TheStreet downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research note on Tuesday, May 13th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Opko Health presently has an average rating of “Buy” and an average target price of $12.13.
The stock’s 50-day moving average is $8.91 and its 200-day moving average is $8.74. The company’s market cap is $3.689 billion.
Opko Health (NYSE:OPK) last announced its earnings results on Friday, May 9th. The company reported ($0.11) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.10) by $0.01. The company had revenue of $22.30 million for the quarter, compared to the consensus estimate of $22.77 million. Analysts expect that Opko Health will post $-0.37 EPS for the current fiscal year.
OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.